Devyn Smith joined Arbor in April, 2021 as Chief Executive Officer and board member. Previously, Devyn was Chief Operations Officer and Head of Strategy at Sigilon Therapeutics, a clinical stage biotechnology company based in Cambridge, MA from 2017 to 2021. At Sigilon, he helped build the company from 10 to over 100 FTEs in four years, built an IND engine with a novel platform focused on delivering 5 INDs in three years, moved from product concept to a product entering clinical trials and raised over $400M in that time.
He is currently a board member and officer for the Alliance of Regenerative Medicine (ARM) the industry group for nearly 400 gene and cell therapy companies. Prior to this he was head of Business Operations and Strategy at the Medicinal Sciences Division at Pfizer R&D. He was previously at Pfizer's Neusentis Research Unit in the UK from 2011-2014 as Chief Operating Officer responsible for strategy and operations for the unit where he helped bring two novel cell therapies and several small molecules from discovery through to clinical trials. Prior to joining Pfizer, Smith was a principal for The Frankel Group (a boutique management consulting firm in New York City and Cambridge).
In his consulting experience, he led a wide range of projects, across multiple therapeutic areas and a host of technology platforms, including basic R&D tools, regenerative medicine, gene therapy, and macromolecules/biologic products. Prior to joining The Frankel Group, Devyn worked as a management consultant at Adventis Corporation focused on clients in information intensive companies. Devyn received his Ph.D. from Harvard Medical School, M.S. from Idaho State University, and a B.S. from Brigham Young University.